Opexa Therapeutics (OPXA) 1.49 $OPXA
RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Thu Apr 10, 9:18AM CDT
RedChip Companies, Inc. ("RedChip"
, an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" television program will feature two emerging growth companies on Fox Business nationwide on Thursday, April 10, 2014 at 10:00 p.m. Pacific (1 a.m. EDT). The show will also air on Bloomberg U.K. Saturday, April 12, 2014 at 12:30 a.m. GMT; on Bloomberg Europe on Sunday, April 13, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday, April 13, 2014 at 3:30 p.m. HKT.
Brinson Patrick Re-launches Research Department
PR Newswire - Thu Apr 10, 7:21AM CDT
Brinson Patrick Securities Corporation ("Brinson Patrick" announced today that the firm has re-launched its equity research department with the recent initiation of coverage on several life sciences companies. The research effort is being spearheaded by Christopher James, M.D., Managing Director and Senior Equity Research Analyst.
Lawsuits, Clinical Studies, Financial Results, and Stock Movements - Analyst Notes on Idenix, BG Medicine, Progenics, Omeros, and Opexa
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), BG Medicine, Inc. (NASDAQ: BGMD), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Omeros Corporation (NASDAQ: OMER), and Opexa Therapeutics, Inc. (NASDAQ: OPXA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register http://www.analystsreview.com/register
Opexa Therapeutics Appoints Prof. Hans-Peter Hartung and Timothy Barabe to the Board of Directors
Business Wire - Thu Mar 20, 7:01AM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the addition of two highly experienced individuals to join the Company's Board of Directors. Hans-Peter Hartung, MD, PhD, FRCP, a world leading clinician and expert in the treatment of Multiple Sclerosis and other neurological diseases, and Timothy Barabe, a proven CFO with global operational and financial expertise, have each been appointed to the Company's Board of Directors, effective March 19th.
Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020
M2 - Mon Mar 10, 7:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gsw6jj/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020" report to their offering. The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4% during 2013 to 2020 The study observed that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5 billion in 2012. Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth. The storage service market was valued at $7.4 billion in 2013. Increase in prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.Cord blood stem cells market is in its emerging phase. Significant applications of stem cells in the treatment of various disorders will be commercialized very soon as most of them are in the last phase of clinical trials. Patents for collection techniques and therapeutics methods are approved by respective government of developed countries however patents for UCB stem cells are comparatively less in developing economies. According to lead analyst Debbie Shields, the geographic analysis shows that the North American market for cord blood stem cell would account for approx. 44% of total revenue generated by the cord blood market in 2013. However, much expected growth is to occur in Asia-Pacific regions during the forecast period, because of growing demand for chronic disease treatments and widely increasing awareness levels. This report study offers updated review about major market players present in this market such as researcher based pharmaceutical companies and therapeutics services companies. Key Market Segments Global Stem cell UCB market by storage - Public cord blood banks - Private cord blood banks - Public Vs. Private UCB banks Global Stem cell UCB market by Diseases - Cancer/ Oncology diseases - Acute Leukemia - Chronic Leukemia - High Risk Solid Tumors - Myelodysplastic Syndrome - Blood diseases - Aplastic Anemia - Beta Thalassemia - Sickle Cell disease - Immune Disorders - Leukocyte Adhesion Deficiency - Hystiocytic Disorders - Wiskott-Aldrich - Metabolic Disorders - Krabbe Disease - Hurler Syndrome - Sanfilippo Syndrome - Other diseases - Osteopetrosis - Hemophagoyticlymphohistiocytosis Global Stem cell UCB market by Technology - Stem Cell Transplant - Autologous transplant - Allogenic transplant - Transplant Medicine - Regenerative Medicine - Others - Cord Blood Banking - Blood Transfusion - Cell Based Genetics Companies Mentioned - Advanced Cell Technology Inc. (USA) - Athersys Inc. - California Stem Cell - Cytori Therapeutics Inc. - Geron Corporation - Mesoblast Limited - NeoStem Inc. - Opexa Therapeutics Inc. - Osiris Therapeutics - Pluristem Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/gs..._stem_cell
Opexa Therapeutics Reports Year End 2013 Financial Results and Provides Corporate Update
Business Wire - Thu Feb 27, 3:20PM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing a novel T-cell immunotherapy for multiple sclerosis (MS), today reported financial results for the year ended December 31, 2013, and provided an overview of recent corporate developments.
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Year End 2013 Financial Results
Business Wire - Wed Feb 26, 7:02AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that the Company will report financial results for the year ended December 31, 2013, at the close of trading on Thursday, February 27, 2014. The Company will also conduct a conference call and webcast to discuss financial results and provide a corporate update at 4:30 P.M. EST on Thursday, February 27.
Opexa Therapeutics CEO to Present at the 2014 Leerink Global Healthcare Conference
Business Wire - Tue Feb 11, 1:16PM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Neil K. Warma, President and Chief Executive Officer, will present at the 2014 Leerink Global Healthcare Conference on Wednesday, February 12, 2014, at 1:00 p.m. EST in the Metropolitan Suite. The conference will be held at the Waldorf-Astoria Hotel in New York, NY.
Opexa Therapeutics to Present at the 16th Annual BIO CEO & Investor Conference
Business Wire - Wed Jan 29, 8:00AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Neil K. Warma, President and Chief Executive Officer, will present at the 16th Annual BIO CEO & Investor Conference on Monday, February 10, 2014, at 11:30 a.m. EST in the Conrad Room. The conference will be held at the Waldorf=Astoria Hotel in New York, NY.
Opexa Therapeutics Chief Scientific Officer Invited as Guest Speaker at the Phacilitate Cell & Gene Therapy Forum
Business Wire - Thu Jan 23, 8:00AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Don Healey, Ph.D., Opexa's Chief Scientific Officer, has been invited as a guest speaker to participate in the Phacilitate Cell & Gene Therapy Forum. The event will take place January 27-29, 2014, at The Grand Hyatt in Washington, DC.
Opexa Therapeutics Inc concludes public offering of 4.12m common shares, including the exercise of over-allotment option
M2 - Tue Dec 24, 8:57AM CST
Biotechnology company Opexa Therapeutics Inc (NasdaqCM:OPXA) revealed on Monday the completion of an underwritten public offering of 4,120,000 shares of its common stock,
Opexa Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Business Wire - Mon Dec 23, 9:18AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the closing of the previously announced underwritten public offering of 4,120,000 shares of its common stock, including the full exercise of the over-allotment option granted to the underwriters to purchase an additional 618,000 shares of its common stock, at a price to the public of $1.70 per share. The gross proceeds to Opexa from this offering were $8,054,600, before deducting underwriting discounts and commissions and other estimated offering expenses and including the full exercise of the over-allotment option. All of the shares in the offering were sold by Opexa.
Apricus Biosciences Inc receives national phase approval for erectile dysfunction cream Vitaros in France
M2 - Fri Dec 20, 5:36AM CST
Pharmaceutical company Apricus Biosciences Inc (NasdaqCM:APRI) reported on Thursday the receipt of National Agency for Medicines and Health Products Safety's (ANSM) national phase approval for Vitaros for the treatment of patients with erectile dysfunction (ED) in France.
Opexa Therapeutics Inc prices public offering at USD1.70 per share
M2 - Wed Dec 18, 3:24AM CST
Biotechnology company Opexa Therapeutics Inc (NasdaqCM:OPXA) said on Tuesday that it has priced an underwritten public offering of 4.12m shares of its common stock.
Opexa Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
Business Wire - Tue Dec 17, 8:15PM CST
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biotechnology company developing Tcelna(R), a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the pricing of an underwritten public offering of 4.12 million shares of its common stock at a price to the public of $1.70 per share. The gross proceeds to Opexa from this offering are expected to be approximately $7 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares in the offering are to be sold by Opexa. Opexa has also granted the underwriters a 45-day option to purchase up to an additional 618,000 shares of common stock to cover over-allotments, if any. The offering is expected to close on or about December 23, 2013, subject to customary closing conditions.
Opexa Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Business Wire - Tue Dec 17, 3:33PM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today announced that it intends to offer shares of its common stock in an underwritten secondary public offering. All of the shares in the offering are to be sold by Opexa. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Opexa Therapeutics Provides MS Trial Enrollment Update; 70% of Patients Enrolled
Business Wire - Mon Dec 16, 7:00AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), is pleased to announce the enrollment of the 126th patient in the Phase IIb "Abili-T" clinical study of Tcelna (imilecleucel-T) in patients with Secondary Progressive Multiple Sclerosis (SPMS).
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H2 2013
M2 - Thu Dec 12, 2:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/cz8w8d/secondary) has announced the addition of the "Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H2 2013" report to their offering. 'Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS). Scope - A snapshot of the global therapeutic scenario for Secondary Progressive Multiple Sclerosis (SPMS). - A review of the Secondary Progressive Multiple Sclerosis (SPMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Secondary Progressive Multiple Sclerosis (SPMS) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Biogen Idec Inc. Novartis AG Opexa Therapeutics, Inc. Innate Therapeutics Limited AB Science Daval International Ltd. For more information visit http://www.researchandmarkets.com/research/cz8w8d/secondary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
New Supply Agreements and Analytical Tools, Expansions, Conference Presentations and Financial Results - Research Report on WuXi PharmaTech, Sirona, ICON, Opexa Therapeutic and Karyopharm Therapeutics
PR Newswire - Wed Nov 20, 8:04AM CST
Editor Note: For more information about this release, please scroll to bottom.
Opexa Therapeutics Selected as a "Top 10 Advanced Therapy Projects to Watch"
Business Wire - Tue Nov 12, 8:00AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced Opexa has been named one of the "Top Projects to Watch" in advanced therapeutics by Elsevier Business Intelligence. As part of this recognition, Neil K. Warma, Opexa's President and Chief Executive Officer, will present a company overview at the Therapeutic Area Partnerships meeting taking place on November 18-20, 2013, at the Hyatt Regency Boston. Mr. Warma will present on Tuesday, November 19 at 2:55 p.m. E.S.T.
RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Thu Apr 10, 9:18AM CDT
RedChip Companies, Inc. ("RedChip"
, an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" television program will feature two emerging growth companies on Fox Business nationwide on Thursday, April 10, 2014 at 10:00 p.m. Pacific (1 a.m. EDT). The show will also air on Bloomberg U.K. Saturday, April 12, 2014 at 12:30 a.m. GMT; on Bloomberg Europe on Sunday, April 13, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday, April 13, 2014 at 3:30 p.m. HKT. Brinson Patrick Re-launches Research Department
PR Newswire - Thu Apr 10, 7:21AM CDT
Brinson Patrick Securities Corporation ("Brinson Patrick"
announced today that the firm has re-launched its equity research department with the recent initiation of coverage on several life sciences companies. The research effort is being spearheaded by Christopher James, M.D., Managing Director and Senior Equity Research Analyst. Lawsuits, Clinical Studies, Financial Results, and Stock Movements - Analyst Notes on Idenix, BG Medicine, Progenics, Omeros, and Opexa
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), BG Medicine, Inc. (NASDAQ: BGMD), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Omeros Corporation (NASDAQ: OMER), and Opexa Therapeutics, Inc. (NASDAQ: OPXA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register http://www.analystsreview.com/register
Opexa Therapeutics Appoints Prof. Hans-Peter Hartung and Timothy Barabe to the Board of Directors
Business Wire - Thu Mar 20, 7:01AM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the addition of two highly experienced individuals to join the Company's Board of Directors. Hans-Peter Hartung, MD, PhD, FRCP, a world leading clinician and expert in the treatment of Multiple Sclerosis and other neurological diseases, and Timothy Barabe, a proven CFO with global operational and financial expertise, have each been appointed to the Company's Board of Directors, effective March 19th.
Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020
M2 - Mon Mar 10, 7:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gsw6jj/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020" report to their offering. The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4% during 2013 to 2020 The study observed that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5 billion in 2012. Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth. The storage service market was valued at $7.4 billion in 2013. Increase in prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.Cord blood stem cells market is in its emerging phase. Significant applications of stem cells in the treatment of various disorders will be commercialized very soon as most of them are in the last phase of clinical trials. Patents for collection techniques and therapeutics methods are approved by respective government of developed countries however patents for UCB stem cells are comparatively less in developing economies. According to lead analyst Debbie Shields, the geographic analysis shows that the North American market for cord blood stem cell would account for approx. 44% of total revenue generated by the cord blood market in 2013. However, much expected growth is to occur in Asia-Pacific regions during the forecast period, because of growing demand for chronic disease treatments and widely increasing awareness levels. This report study offers updated review about major market players present in this market such as researcher based pharmaceutical companies and therapeutics services companies. Key Market Segments Global Stem cell UCB market by storage - Public cord blood banks - Private cord blood banks - Public Vs. Private UCB banks Global Stem cell UCB market by Diseases - Cancer/ Oncology diseases - Acute Leukemia - Chronic Leukemia - High Risk Solid Tumors - Myelodysplastic Syndrome - Blood diseases - Aplastic Anemia - Beta Thalassemia - Sickle Cell disease - Immune Disorders - Leukocyte Adhesion Deficiency - Hystiocytic Disorders - Wiskott-Aldrich - Metabolic Disorders - Krabbe Disease - Hurler Syndrome - Sanfilippo Syndrome - Other diseases - Osteopetrosis - Hemophagoyticlymphohistiocytosis Global Stem cell UCB market by Technology - Stem Cell Transplant - Autologous transplant - Allogenic transplant - Transplant Medicine - Regenerative Medicine - Others - Cord Blood Banking - Blood Transfusion - Cell Based Genetics Companies Mentioned - Advanced Cell Technology Inc. (USA) - Athersys Inc. - California Stem Cell - Cytori Therapeutics Inc. - Geron Corporation - Mesoblast Limited - NeoStem Inc. - Opexa Therapeutics Inc. - Osiris Therapeutics - Pluristem Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/gs..._stem_cell
Opexa Therapeutics Reports Year End 2013 Financial Results and Provides Corporate Update
Business Wire - Thu Feb 27, 3:20PM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing a novel T-cell immunotherapy for multiple sclerosis (MS), today reported financial results for the year ended December 31, 2013, and provided an overview of recent corporate developments.
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Year End 2013 Financial Results
Business Wire - Wed Feb 26, 7:02AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that the Company will report financial results for the year ended December 31, 2013, at the close of trading on Thursday, February 27, 2014. The Company will also conduct a conference call and webcast to discuss financial results and provide a corporate update at 4:30 P.M. EST on Thursday, February 27.
Opexa Therapeutics CEO to Present at the 2014 Leerink Global Healthcare Conference
Business Wire - Tue Feb 11, 1:16PM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Neil K. Warma, President and Chief Executive Officer, will present at the 2014 Leerink Global Healthcare Conference on Wednesday, February 12, 2014, at 1:00 p.m. EST in the Metropolitan Suite. The conference will be held at the Waldorf-Astoria Hotel in New York, NY.
Opexa Therapeutics to Present at the 16th Annual BIO CEO & Investor Conference
Business Wire - Wed Jan 29, 8:00AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Neil K. Warma, President and Chief Executive Officer, will present at the 16th Annual BIO CEO & Investor Conference on Monday, February 10, 2014, at 11:30 a.m. EST in the Conrad Room. The conference will be held at the Waldorf=Astoria Hotel in New York, NY.
Opexa Therapeutics Chief Scientific Officer Invited as Guest Speaker at the Phacilitate Cell & Gene Therapy Forum
Business Wire - Thu Jan 23, 8:00AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Don Healey, Ph.D., Opexa's Chief Scientific Officer, has been invited as a guest speaker to participate in the Phacilitate Cell & Gene Therapy Forum. The event will take place January 27-29, 2014, at The Grand Hyatt in Washington, DC.
Opexa Therapeutics Inc concludes public offering of 4.12m common shares, including the exercise of over-allotment option
M2 - Tue Dec 24, 8:57AM CST
Biotechnology company Opexa Therapeutics Inc (NasdaqCM:OPXA) revealed on Monday the completion of an underwritten public offering of 4,120,000 shares of its common stock,
Opexa Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Business Wire - Mon Dec 23, 9:18AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the closing of the previously announced underwritten public offering of 4,120,000 shares of its common stock, including the full exercise of the over-allotment option granted to the underwriters to purchase an additional 618,000 shares of its common stock, at a price to the public of $1.70 per share. The gross proceeds to Opexa from this offering were $8,054,600, before deducting underwriting discounts and commissions and other estimated offering expenses and including the full exercise of the over-allotment option. All of the shares in the offering were sold by Opexa.
Apricus Biosciences Inc receives national phase approval for erectile dysfunction cream Vitaros in France
M2 - Fri Dec 20, 5:36AM CST
Pharmaceutical company Apricus Biosciences Inc (NasdaqCM:APRI) reported on Thursday the receipt of National Agency for Medicines and Health Products Safety's (ANSM) national phase approval for Vitaros for the treatment of patients with erectile dysfunction (ED) in France.
Opexa Therapeutics Inc prices public offering at USD1.70 per share
M2 - Wed Dec 18, 3:24AM CST
Biotechnology company Opexa Therapeutics Inc (NasdaqCM:OPXA) said on Tuesday that it has priced an underwritten public offering of 4.12m shares of its common stock.
Opexa Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
Business Wire - Tue Dec 17, 8:15PM CST
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biotechnology company developing Tcelna(R), a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the pricing of an underwritten public offering of 4.12 million shares of its common stock at a price to the public of $1.70 per share. The gross proceeds to Opexa from this offering are expected to be approximately $7 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares in the offering are to be sold by Opexa. Opexa has also granted the underwriters a 45-day option to purchase up to an additional 618,000 shares of common stock to cover over-allotments, if any. The offering is expected to close on or about December 23, 2013, subject to customary closing conditions.
Opexa Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Business Wire - Tue Dec 17, 3:33PM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today announced that it intends to offer shares of its common stock in an underwritten secondary public offering. All of the shares in the offering are to be sold by Opexa. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Opexa Therapeutics Provides MS Trial Enrollment Update; 70% of Patients Enrolled
Business Wire - Mon Dec 16, 7:00AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), is pleased to announce the enrollment of the 126th patient in the Phase IIb "Abili-T" clinical study of Tcelna (imilecleucel-T) in patients with Secondary Progressive Multiple Sclerosis (SPMS).
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H2 2013
M2 - Thu Dec 12, 2:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/cz8w8d/secondary) has announced the addition of the "Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H2 2013" report to their offering. 'Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS). Scope - A snapshot of the global therapeutic scenario for Secondary Progressive Multiple Sclerosis (SPMS). - A review of the Secondary Progressive Multiple Sclerosis (SPMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Secondary Progressive Multiple Sclerosis (SPMS) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Biogen Idec Inc. Novartis AG Opexa Therapeutics, Inc. Innate Therapeutics Limited AB Science Daval International Ltd. For more information visit http://www.researchandmarkets.com/research/cz8w8d/secondary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
New Supply Agreements and Analytical Tools, Expansions, Conference Presentations and Financial Results - Research Report on WuXi PharmaTech, Sirona, ICON, Opexa Therapeutic and Karyopharm Therapeutics
PR Newswire - Wed Nov 20, 8:04AM CST
Editor Note: For more information about this release, please scroll to bottom.
Opexa Therapeutics Selected as a "Top 10 Advanced Therapy Projects to Watch"
Business Wire - Tue Nov 12, 8:00AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced Opexa has been named one of the "Top Projects to Watch" in advanced therapeutics by Elsevier Business Intelligence. As part of this recognition, Neil K. Warma, Opexa's President and Chief Executive Officer, will present a company overview at the Therapeutic Area Partnerships meeting taking place on November 18-20, 2013, at the Hyatt Regency Boston. Mr. Warma will present on Tuesday, November 19 at 2:55 p.m. E.S.T.
